<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="rchop-mtx-cns-prophylaxis-dlbcl-lang">
    <meta name="study:title" content="PF955 - Intravenous middle-dose methotrexate incorporated into R-CHOP prevented central nervous system relapse in high-risk diffuse large B-cell lymphoma patients: A single-center retrospective study">
    <meta name="study:fileName" content="Abstracts/RCHOP-MTX-CNS-PROPHYLAXIS-DLBCL-LANG.html">
    <meta name="study:cancerTypes" content="DLBCL,LBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="1L">
    <meta name="study:evidenceType" content="Real-world evidence"> <meta name="study:drugs" content="Methotrexate,MTX,Rituximab,Monoclonal Antibody,Cyclophosphamide,Doxorubicin,Vincristine,Prednisone,Chemotherapy,CIT,R-CHOP">

    <title>PF955: R-CHOP + MTX for CNS Prophylaxis in High-Risk DLBCL (Lang) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css">
</head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PF955 - R-CHOP + MTX for CNS Prophylaxis in High-Risk DLBCL</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996-2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0 2.706.39 3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim (N=1135 Total)</h4>
                    <p>Newly diagnosed DLBCL. High-risk defined by extranodal sites. Aim: Eval MTX + R-CHOP for CNS relapse prevention.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path fill-rule="evenodd" d="M10.5 3.75a.75.75 0 01.75-.75h1.5a.75.75 0 01.75.75V4.5h3A2.25 2.25 0 0118.75 6.75v1.5a2.25 2.25 0 01-2.25 2.25H15.5V12h1.25a.75.75 0 010 1.5H15.5v1.5h.75a.75.75 0 010 1.5H15.5v1.5H18a.75.75 0 010 1.5h-2.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0v-3A2.25 2.25 0 016 14.25v-1.5A2.25 2.25 0 018.25 10.5H9.5V9H8.25A2.25 2.25 0 016 6.75v-1.5A2.25 2.25 0 018.25 3H10.5V3.75zm-1.5 6.75h6V6.75H9V10.5z" clip-rule="evenodd" />
                    </svg>
                    <h4>Intervention (High-Risk Group)</h4>
                    <p>CNS Prophylaxis: 4 cycles MTX 1.0g/m² + R-CHOP. Compared to no prophylaxis. Retrospective.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path d="M3 13.5a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 13.5zM3 8.25a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 8.25zM3 18.75a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 18.75zM20.25 3a.75.75 0 00-.75.75v16.5a.75.75 0 001.5 0V3.75a.75.75 0 00-.75-.75z" />
                        <path fill-rule="evenodd" d="M9.97 4.28a.75.75 0 01.75-.75H12a.75.75 0 01.75.75v10.174l3.108-3.293a.75.75 0 111.084 1.038l-4.5 4.75a.75.75 0 01-1.084 0l-4.5-4.75a.75.75 0 111.084-1.038L9.97 14.454V4.28z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Efficacy (High-Risk Group)</h4>
                    <p>2-yr Cum. CNS Relapse: <br>With MTX Proph: <span class="highlight-value">4.9%</span><br>W/o MTX Proph: <span class="highlight-value">9.5%</span> (p=0.221)</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm-.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Conclusion</h4>
                    <p>CNS-IPI effective predictor. Middle-dose MTX + R-CHOP shows trend for lower CNS relapse in high-risk DLBCL.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PF955 - Intravenous middle-dose methotrexate incorporated into R-CHOP prevented central nervous system relapse in high-risk diffuse large B-cell lymphoma patients: A single-center retrospective study</h1>
            <p class="abstract-sub-header">Min Lang, Chao Chen, Hui-ying Zhu, et al.</p>
            <p class="abstract-meta-info mt-2">EHA 2025 Congress | Abstract #PF955 | Poster Presentation</p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>CNS relapse in DLBCL: ~5% overall, >10% in high-risk patients.</li>
                        <li>Secondary CNS involvement has poor prognosis.</li>
                        <li>CNS-IPI (based on IPI, renal/adrenal involvement) is widely used for predicting CNS recurrence.</li>
                        <li>Prevention of CNS relapse is a key concern.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <p class="text-sm mb-1">To investigate whether 4 cycles of MTX 1.0g/m² combined with R-CHOP can effectively reduce CNS recurrence in high-risk DLBCL patients.</p>
                    <p class="text-xs meta-info mt-1">High-risk defined as: involvement of >1 extranodal site, OR involvement of bone marrow, breasts, testes, paranasal sinuses, epidural space, adrenal glands, kidney, or female genital system.</p>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li>Single-center retrospective analysis (Peking Union Medical Hospital, June 2003 - Dec 2024).</li>
                        <li>Patients: Newly diagnosed DLBCL. Excluded: primary CNS lymphoma, intravascular LBCL with CNS involvement.</li>
                        <li>Data Collection: Electronic medical records, clinical/telephone follow-up (final: Dec 31, 2024).</li>
                        <li>CNS Prophylaxis Protocol: 4 cycles of MTX 1.0g/m² combined with R-CHOP.</li>
                    </ul>
                     <div class="study-design-schema">
                        <h3 class="schema-title">Retrospective Analysis Overview</h3>
                        <div class="schema-enrollment">
                            <strong>DLBCL Patients (N=1135)</strong>
                            <span>(June 2003 - Dec 2024)</span>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-phase-group">
                            <div class="schema-phase" style="flex-basis: 48%; background-color: var(--sobi-light-teal-bg);">
                                <strong>High-Risk for CNS Relapse (N=328 by CNS-IPI ≥4; also defined by extranodal sites)</strong>
                                <span class="text-xs mt-1">81 (24.7%) received MTX + R-CHOP Prophylaxis</span>
                                <span class="text-xs">247 (75.3%) did not receive prophylaxis</span>
                            </div>
                             <div class="schema-phase" style="flex-basis: 48%; background-color: var(--sobi-light-orange-bg);">
                                <strong>Low-Risk for CNS Relapse (N=807 by CNS-IPI <4)</strong>
                                 <span class="text-xs mt-1">141 (17.5%) received MTX + R-CHOP Prophylaxis</span>
                                <span class="text-xs">666 (82.5%) did not receive prophylaxis</span>
                            </div>
                        </div>
                        <div class="schema-assessment-points">
                           <span>CNS Recurrence Rates</span>
                           <span>Overall Survival (OS)</span>
                           <span>Progression-Free Survival (PFS)</span>
                        </div>
                    </div>
                </div>
            </div>

            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Patient Characteristics (Overall, N=1135)</h2>
                    <div class="table-container">
                        <table>
                            <thead>
                                <tr><th>Characteristic</th><th>Value</th></tr>
                            </thead>
                            <tbody>
                                <tr><td>Male to Female Ratio</td><td>0.94:1</td></tr>
                                <tr><td>Median Age at Diagnosis, years (range)</td><td>59 (14-94)</td></tr>
                                <tr><td>Stage I/II (N=1130 evaluable)</td><td>334 (29.6%)</td></tr>
                                <tr><td>Stage III/IV (N=1130 evaluable)</td><td>796 (70.4%)</td></tr>
                                <tr><td>IPI Score 0-2</td><td>582</td></tr>
                                <tr><td>IPI Score 3-5</td><td>553</td></tr>
                                <tr><td>CNS-IPI ≥4 (High-Risk), n (%)</td><td>328 (28.9%)</td></tr>
                                <tr><td>CNS-IPI <4 (Low-Risk), n (%)</td><td>807 (71.1%)</td></tr>
                            </tbody>
                        </table>
                    </div>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Efficacy Results (Median F/U: 17 months)</h2>
                    <p class="text-sm mb-2"><strong>Overall Cohort (N=1135):</strong></p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2 mb-3">
                        <li>2-year OS: 87.2%</li>
                        <li>2-year PFS: 69.9%</li>
                        <li>Total CNS Recurrence: 36 patients (3.2%)</li>
                        <li>2-year Cumulative CNS Relapse Rate: 4.1%</li>
                    </ul>
                     <p class="text-sm mb-2"><strong>CNS Recurrence by Risk Group (CNS-IPI based):</strong></p>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2 mb-3">
                        <li>High-Risk Group (CNS-IPI ≥4, N=328): 4.9% (16 Pts)</li>
                        <li>Low-Risk Group (CNS-IPI <4, N=807): 2.5% (20 Pts) (p=0.041)</li>
                    </ul>
                    <p class="text-sm mb-2"><strong>CNS Recurrence in High-Risk Group (CNS-IPI ≥4) by Prophylaxis:</strong></p>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2 mb-3">
                        <li>With MTX Prophylaxis (N=81): 3.7%</li>
                        <li>Without MTX Prophylaxis (N=247): 5.3% (p=0.769, not significant)</li>
                        <li><strong>2-year Cumulative CNS Relapse Rate:</strong>
                            <ul class="list-circle list-inside ml-4">
                                <li>With MTX Prophylaxis: 4.9%</li>
                                <li>Without MTX Prophylaxis: 9.5% (p=0.221)</li>
                            </ul>
                        </li>
                    </ul>
                    <div class="chart-container mb-6">
                        <svg id="cnsRelapseChart" width="400" height="300"></svg>
                        <div id="cnsRelapseLegend" class="legend"></div>
                    </div>
                     <div class="grid grid-cols-1 md:grid-cols-2 gap-4 mt-4">
                        <div class="km-plot-container zoomable-image-container">
                            <img src="https://storage.googleapis.com/generativeai-downloads/ESH2025/PF955_Fig1a_OS_PFS.png" alt="Overall Survival and Progression-Free Survival of Overall Patients" class="zoomable-image" onerror="this.onerror=null; this.src='https://placehold.co/400x300/E0F2F7/0A2F5C?text=OS/PFS+Curve+Not+Available';">
                            <p class="text-xs text-center mt-1">Figure 1a: OS/PFS of Overall Patients (Adapted from Abstract)</p>
                        </div>
                        <div class="km-plot-container zoomable-image-container">
                             <img src="https://storage.googleapis.com/generativeai-downloads/ESH2025/PF955_Fig1b_CNS_Relapse.png" alt="Cumulative CNS Relapse Rate in High-Risk Group" class="zoomable-image" onerror="this.onerror=null; this.src='https://placehold.co/400x300/FFF0E5/0A2F5C?text=CNS+Relapse+Curve+Not+Available';">
                            <p class="text-xs text-center mt-1">Figure 1b: Cumulative CNS Relapse Rate (High-Risk Group) (Adapted from Abstract)</p>
                        </div>
                    </div>
                </div>
                 <div class="abstract-card">
                    <h2 class="abstract-section-title">Safety Summary</h2>
                     <p class="text-sm">Safety details of the MTX + R-CHOP regimen were not specifically reported in this abstract.</p>
                </div>
            </div>
        </div>

        <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>CNS-IPI is an effective predictive model for CNS recurrence in DLBCL.</li>
                <li>After prevention with middle-dose MTX (1.0g/m² x4) combined with R-CHOP, the CNS relapse rate in high-risk DLBCL patients was lower than in those who did not receive CNS prevention (2-year cumulative: 4.9% vs 9.5%, p=0.221).</li>
                <li>This suggests the MTX prophylaxis method is effective, although the difference in this retrospective analysis did not reach statistical significance for all compared metrics.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <p>CHOP, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone; CIT, Chemoimmunotherapy; CNS, Central Nervous System; CR, Complete Remission; DLBCL, Diffuse Large B-Cell Lymphoma; F/U, Follow-up; IPI, International Prognostic Index; MTX, Methotrexate; OS, Overall Survival; PFS, Progression-Free Survival; PR, Partial Remission; R, Rituximab; R-CHOP, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone.</p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">
                Lang M, Chen C, Zhu HY, et al. Intravenous middle-dose methotrexate incorporated into R-CHOP prevented central nervous system relapse in high-risk diffuse large B-cell lymphoma patients: A single-center retrospective study. Abstract #PF955 presented at European Haematology Association (EHA) June 12–15, 2025, Milan, Italy.
            </p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA 2025 Congress | Abstract #PF955 | Abstract Release: 05/14/2025 | Presentation: 06/13/2025</p>
            <p>Embargoed until Thursday, June 12, 2025, 08:00 CEST. For Research & Informational Purposes Only.</p>
        </div>
    </div>

    <script defer src="abstract_features.js"></script>
    <script>
        function drawCnsRelapseChart(containerId, legendContainerId) {
            const chartTitle = "2-Year Cumulative CNS Relapse Rate (High-Risk Group)";
            // Data from abstract text for high-risk patients
            const chartData = [
                { group: "With MTX Prophylaxis (N=81)", value: 4.9 },
                { group: "Without MTX Prophylaxis (N=247)", value: 9.5 }
            ];
            const pValue = 0.221;

            const svg = d3.select(containerId);
            const legendContainer = d3.select(legendContainerId);

            svg.selectAll("*").remove();
            legendContainer.selectAll("*").remove(); // Clear previous legend

            let containerWidth = 400;
            const chartWrapper = svg.node() ? svg.node().closest('.chart-container') : null;
            if (chartWrapper) {
                containerWidth = Math.max(chartWrapper.getBoundingClientRect().width * 0.9, 300);
            }
            
            const svgWidth = containerWidth;
            const svgHeight = +svg.attr("height");

            const margin = { top: 50, right: 20, bottom: 70, left: 60 }; // Increased bottom margin for p-value
            const chartWidth = svgWidth - margin.left - margin.right;
            const chartHeight = svgHeight - margin.top - margin.bottom;

            if (chartWidth <= 0 || chartHeight <=0) return;

            const g = svg.append("g")
                .attr("transform", `translate(${margin.left},${margin.top})`);

            const groups = chartData.map(d => d.group);
            
            const xScale = d3.scaleBand()
                .domain(groups)
                .range([0, chartWidth])
                .padding(0.4);

            const yScale = d3.scaleLinear()
                .domain([0, d3.max(chartData, d => d.value) * 1.2 || 10]) // Dynamic Y-axis, ensure at least 10
                .range([chartHeight, 0]);

            const colorScale = d3.scaleOrdinal()
                .domain(groups)
                .range(["var(--sobi-teal)", "var(--sobi-orange)"]);

            g.append("g")
                .attr("transform", `translate(0,${chartHeight})`)
                .call(d3.axisBottom(xScale))
                .selectAll("text")
                .attr("class", "axis-text")
                .style("font-size", "10px")
                .attr("transform", "rotate(-15) translate(-5,0)")
                .style("text-anchor", "end");


            g.append("g")
                .call(d3.axisLeft(yScale).ticks(5).tickFormat(d => d.toFixed(1) + "%"))
                .selectAll("text")
                .attr("class", "axis-text")
                .style("font-size", "10px");

            g.append("g")			
                .attr("class", "grid")
                .call(d3.axisLeft(yScale)
                    .ticks(5)
                    .tickSize(-chartWidth)
                    .tickFormat("")
                )
                .selectAll("line")
                .style("stroke", "#e0e0e0")
                .style("stroke-opacity", "0.7");

            g.selectAll(".bar")
                .data(chartData)
                .enter().append("rect")
                  .attr("class", "bar")
                  .attr("x", d => xScale(d.group))
                  .attr("y", d => yScale(d.value))
                  .attr("width", xScale.bandwidth())
                  .attr("height", d => chartHeight - yScale(d.value))
                  .attr("fill", d => colorScale(d.group))
                  .attr("rx", 3).attr("ry", 3);
            
            g.selectAll(".bar-label")
                .data(chartData)
                .enter().append("text")
                .attr("class", "chart-label")
                .attr("x", d => xScale(d.group) + xScale.bandwidth() / 2)
                .attr("y", d => yScale(d.value) - 5) 
                .attr("text-anchor", "middle")
                .style("font-size", "10px")
                .style("fill", "var(--sobi-dark-text)")
                .text(d => `${d.value.toFixed(1)}%`);
            
            svg.append("text")
                .attr("x", svgWidth / 2)
                .attr("y", margin.top / 2)
                .attr("text-anchor", "middle")
                .style("font-size", "14px")
                .style("font-weight", "600")
                .style("fill", "var(--sobi-dark-blue)")
                .text(chartTitle);

            // Add p-value text
            svg.append("text")
                .attr("x", svgWidth / 2)
                .attr("y", chartHeight + margin.top + 45) // Position below x-axis
                .attr("text-anchor", "middle")
                .style("font-size", "10px")
                .style("font-weight", pValue < 0.05 ? "bold" : "normal")
                .style("fill", pValue < 0.05 ? "var(--sobi-orange)" : "var(--sobi-dark-text)")
                .text(`p = ${pValue.toFixed(3)}`);


            // Legend (Optional, as colors are distinct and labels are on x-axis)
            // If a legend is desired:
            const legendData = chartData.map(d => ({
                label: d.group,
                color: colorScale(d.group)
            }));

            const legendItems = legendContainer.selectAll(".legend-item")
                .data(legendData).enter().append("div").attr("class", "legend-item");
            legendItems.append("div").attr("class", "legend-color-box").style("background-color", d => d.color);
            legendItems.append("span").text(d => d.label);
        }
        
        function debounce(func, wait) {
            let timeout;
            return function executedFunction(...args) {
                const later = () => {
                    clearTimeout(timeout);
                    func(...args);
                };
                clearTimeout(timeout);
                timeout = setTimeout(later, wait);
            };
        };

        const debouncedDrawPF955Chart = debounce(() => drawCnsRelapseChart("#cnsRelapseChart", "#cnsRelapseLegend"), 250);
        
        window.addEventListener('resize', debouncedDrawPF955Chart);
        
        document.addEventListener('DOMContentLoaded', () => {
            debouncedDrawPF955Chart();
        });
        if (document.readyState === "complete" || document.readyState === "interactive") {
             setTimeout(debouncedDrawPF955Chart, 0); 
        }
    </script>
</body>
</html>
